



Release no. 18/2012

NASDAQ OMX Copenhagen to accept delisting request provided a new offer from Trans Nova

Copenhagen and Oslo, 6th July, 2012

Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced today NASDAQ OMX Copenhagen has responded to Affitech's application as of May 31st for delisting of the Company. NASDAQ OMX will accept the request from Affitech provided that Trans Nova Investment Limited (Trans Nova) the largest shareholder owning 71.3% of the shares, prepares a new offer to Affitech's other shareholders. This offer must be prepared according to the regulations for compulsory redemption and the shareholders must get a fair deadline for acceptance. Delisting may take place within a deadline of six weeks from the announcement of the result of a renewed offer.

Affitech's Board has informed Trans Nova of the decision of NASDAQ OMX. Trans Nova will now decide how to proceed.

Contact:

*Randi Krogsgaard, Director IR & Corporate Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com*

About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The Company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules. Affitech co-develops its two lead antibody drug programs AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. The Company's initial focus is on rapid and cost effective development by partnering clinical trials in emerging markets. Further information is available at www.affitech.com.

Disclaimer

This announcement may contain forward-looking statements including statements about Affitech's expectations of the progression of its pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on Management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Affitech cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for

new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.